vorinostat has been researched along with Body Weight in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animals were dosed on Gestation Days 6-20 or 7-20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively." | 1.34 | Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. ( Kerr, JS; Turner, KJ; Wise, LD, 2007) |
| " Four compounds having an MTD > or = 100 mg/kg were selected for dose-response studies in the HCT116 xenograft model." | 1.32 | N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). ( Atadja, P; Bair, KW; Bontempo, J; Cesarz, D; Chandramouli, N; Chen, R; Cheung, M; Cornell-Kennon, S; Dean, K; Diamantidis, G; France, D; Green, MA; Howell, KL; Kashi, R; Kwon, P; Lassota, P; Martin, MS; Mou, Y; Perez, LB; Remiszewski, SW; Sambucetti, LC; Sharma, S; Smith, T; Sorensen, E; Taplin, F; Trogani, N; Versace, R; Walker, H; Weltchek-Engler, S; Wood, A; Wu, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Remiszewski, SW | 1 |
| Sambucetti, LC | 1 |
| Bair, KW | 1 |
| Bontempo, J | 1 |
| Cesarz, D | 1 |
| Chandramouli, N | 1 |
| Chen, R | 1 |
| Cheung, M | 1 |
| Cornell-Kennon, S | 1 |
| Dean, K | 1 |
| Diamantidis, G | 1 |
| France, D | 1 |
| Green, MA | 1 |
| Howell, KL | 1 |
| Kashi, R | 1 |
| Kwon, P | 1 |
| Lassota, P | 1 |
| Martin, MS | 1 |
| Mou, Y | 1 |
| Perez, LB | 1 |
| Sharma, S | 1 |
| Smith, T | 1 |
| Sorensen, E | 1 |
| Taplin, F | 1 |
| Trogani, N | 1 |
| Versace, R | 1 |
| Walker, H | 1 |
| Weltchek-Engler, S | 1 |
| Wood, A | 1 |
| Wu, A | 1 |
| Atadja, P | 1 |
| McGee-Lawrence, ME | 1 |
| McCleary-Wheeler, AL | 1 |
| Secreto, FJ | 1 |
| Razidlo, DF | 1 |
| Zhang, M | 1 |
| Stensgard, BA | 1 |
| Li, X | 1 |
| Stein, GS | 1 |
| Lian, JB | 1 |
| Westendorf, JJ | 1 |
| Casto, BC | 1 |
| Pereira, MA | 1 |
| Wise, LD | 2 |
| Turner, KJ | 1 |
| Kerr, JS | 2 |
| Spence, S | 1 |
| Saldutti, LP | 1 |
5 other studies available for vorinostat and Body Weight
| Article | Year |
|---|---|
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Topics: Acetyltransferases; Acrylamides; Animals; Antineoplastic Agents; Body Weight; Cell Division; Dose-Re | 2003 |
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Topics: Acetylation; Animals; Biomarkers; Body Weight; Bone Marrow Cells; Bone Remodeling; Bone Resorption; | 2011 |
Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Body Weight; Budesonide; Chemop | 2011 |
Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Dose-Response Relationship, Drug; Enzyme Inhibito | 2007 |
Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.
Topics: Administration, Oral; Animals; Body Weight; Dose-Response Relationship, Drug; Embryonic Development; | 2008 |